Research
Hormonal
GLP-1 receptor agonists have better side-effect profiles than other weight management treatments.
Healthcare providers may prefer GLP-1 receptor agonists for patients due to their favorable side-effect profiles.
StrongSupportsmedium confidence
with better side-effect profiles than other treatments.
Why this rating
The claim is based on comparative safety data.
Source
Next Chapter for Weight Control — Small-Molecule GLP-1 Receptor Agonists?
E. Dale Abel · New England Journal of Medicine · 2023
DOI 10.1056/nejme2307285
reviewCited 7×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →